Diabetic retinopathy affects nearly all young patients with type 1 diabetes

Article

One in three young Danish patients with type 1 diabetes mellitus progressed to proliferative diabetic retinopathy, and two in three had 2-step progression despite their young age, according to study results recently published in the November 2013 issue of Acta Diabetologica. In addition, these researchers from Denmark found that after 30-years? duration of diabetes, the presence of diabetic retinopathy was almost universal.

One in three young Danish patients with type 1 diabetes mellitus progressed to proliferative diabetic retinopathy, and two in three had 2-step progression despite their young age, according to study results recently published in Acta Diabetologica. In addition, these researchers from Denmark found that after 30-years' duration of diabetes, the presence of diabetic retinopathy was almost universal.

From 1987 to 1989, these researchers identified a paediatric cohort of children that included approximately 75% of all children in Denmark with type 1 diabetes

In 1995, mean patient age was 21.0 years, and mean duration of diabetes was 13.5 years. The 16-year incidence of proliferative retinopathy was 31.0%, 2-step progression was 64.4% and 2-step regression of diabetic retinopathy was 0.0%. The incidence of diabetic retinopathy was 95.1%.

Upon multivariate logistic regression modelling, progression to proliferative diabetic retinopathy was significantly associated with HbA1c levels in 1995 (OR: 2.61 per 1% increase, 95% CI: 1.85-3.68) and diastolic BP of 1995 (OR: 1.79 per 10 mmHg increase, 95% CI: 1.04-3.07). Two-step progression of diabetic retinopathy was associated with male gender (OR: 2.37 versus female, 95% CI: 1.07-5.27), 1995 HbA1c (OR: 3.02per 1% increase, 95% CI: 2.04-4.48), and 1995 vibration perception threshold (OR: 1.19 per 1 volt increase, 95% CI: 1.02-1.40).

To access these data, click here.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.